FDA Grants Accelerated Approval to Dordaviprone in Diffuse Midline Glioma
Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.
Previous Post
Creating a Seamless Transition from Pediatric to Adult Patient Cancer Care
Next Post
Factors to Consider When Choosing the Right Disease-Modifying Therapy for Newly Diagnosed MS
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago